Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Dietary phytochemicals and neuro-inflammaging: from mechanistic insights to translational challenges.
Relationship between vitamin D deficiency and visually evoked potentials in multiple sclerosis.
Correction: Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study.
Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice.
Mucosal-Associated Invariant T Cells in Multiple Sclerosis: The Jury is Still Out.
Effectiveness of muscle basal lamina carrying neural stem cells and olfactory ensheathing cells in spinal cord repair.
Translational Biomarkers of Neurotoxicity: A Health and Environmental Sciences Institute Perspective on the Way Forward.
Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis.
Acute transverse myelitis in a child with lyme disease and a review of literature.
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
Th17 cells in autoimmune diseases.
Focal MMP-2 and MMP-9 Activity at the Blood-Brain Barrier Promotes Chemokine-Induced Leukocyte Migration.
Acute autonomic, sensory and motor neuropathy associated with meningoencephalitis.
Clinical and demographic factors affecting disease severity in patients with multiple sclerosis.
Bladder management in multiple sclerosis.
Do Patients With Multiple Sclerosis Show Different Daily Physical Activity Patterns From Healthy Individuals?
Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?
Ninjurin1 enhances the basal motility and transendothelial migration of immune cells by inducing protrusive membrane dynamics.
Myelin Basic Protein-primed T Helper 2 Cells Suppress Microglial Activation via AlphaVBeta3 Integrin: Implications for Multiple Sclerosis.
[The cost-effectiveness of interferon beta treatment in patients with a clinically isolated syndrome in Colombia].
In vivo quantification of demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy.
Gait variability in people with neurological disorders: A systematic review and meta-analysis.
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis.
ASP4058, a Novel Agonist for Sphingosine 1-Phosphate Receptors 1 and 5, Ameliorates Rodent Experimental Autoimmune Encephalomyelitis with a Favorable Safety Profile.
Pages
« first
‹ previous
…
615
616
617
618
619
620
621
622
623
…
next ›
last »